UTHR

United Therapeutics Corp

524.36

USD

UTHR Earnings Reports

Positive Surprise Ratio

UTHR beat 21 of 41 last estimates.

51%

Next Report

Date of Next Report

Apr 28, 2026

Estimate for Q1 26 (Revenue/ EPS)

$825.73M

$7.08

Implied change from Q4 25 (Revenue/ EPS)

+4.50%

-8.05%

Implied change from Q1 25 (Revenue/ EPS)

+3.94%

+6.79%

United Therapeutics Corp earnings per share and revenue

On Feb 25, 2026, UTHR reported earnings of 7.70 USD per share (EPS) for Q4 25, beating the estimate of 7.32 USD, resulting in a 5.05% surprise. Revenue reached 790.20 million, compared to an expected 829.34 million, with a -4.72% difference. The market reacted with a +13.03% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 8 analysts forecast an EPS of 7.08 USD, with revenue projected to reach 825.73 million USD, implying an decrease of -8.05% EPS, and increase of 4.50% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Oruka Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.64

Actual

-$0.45

Surprise

+29.69%

Nektar Therapeutics

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$2.52

Actual

-$1.78

Surprise

+29.47%

Savara Inc.

Report Date

Mar 13, 2026 For Q4 25

Estimate

-$0.12

Actual

-$0.13

Surprise

-8.15%

Lyell Immunopharma, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$2.27

Actual

-$7.50

Surprise

-229.53%

Relmada Therapeutics, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.14

Actual

-$0.27

Surprise

-89.08%

Century Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.28

Actual

-$0.22

Surprise

+23.88%

Tonix Pharmaceuticals Holding Corp.

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$3.25

Actual

-$3.98

Surprise

-22.32%

Korro Bio, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$2.10

Actual

-$1.65

Surprise

+21.74%

Verrica Pharmaceuticals Inc. Common Stock

Report Date

Mar 11, 2026 For Q4 25

Estimate

-$0.81

Actual

-$0.46

Surprise

+43.22%

Champions Oncology, Inc.

Report Date

Mar 12, 2026 For Q3 26

Estimate

$0.09

Actual

-$0.02

Surprise

-121.79%

FAQ

What were United Therapeutics Corp's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, United Therapeutics Corp reported EPS of $7.70, beating estimates by 5.05%, and revenue of $790.20M, -4.72% below expectations.

How did the market react to United Therapeutics Corp's Q4 2025 earnings?

The stock price moved up 13.03%, changed from $473.43 before the earnings release to $535.10 the day after.

When is United Therapeutics Corp expected to report next?

The next earning report is scheduled for Apr 28, 2026.

What are the forecasts for United Therapeutics Corp's next earnings report?

Based on 8 analysts, United Therapeutics Corp is expected to report EPS of $7.08 and revenue of $825.73M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.